What is the official website of Accelerated Enrollment Solutions ?

The official website of Accelerated Enrollment Solutions is https://trialmed.com/.

What is Accelerated Enrollment Solutions's cybersecurity risk score?

Accelerated Enrollment Solutions has an AI-generated cybersecurity risk score of 756 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Accelerated Enrollment Solutions experienced?

According to Rankiteo, Accelerated Enrollment Solutions currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Accelerated Enrollment Solutions been affected by any supply chain cyber incidents ?

According to Rankiteo, Accelerated Enrollment Solutions has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Accelerated Enrollment Solutions have SOC 2 Type 1 certification ?

According to Rankiteo, Accelerated Enrollment Solutions is not certified under SOC 2 Type 1.

Does Accelerated Enrollment Solutions have SOC 2 Type 2 certification ?

According to Rankiteo, Accelerated Enrollment Solutions does not hold a SOC 2 Type 2 certification.

Does Accelerated Enrollment Solutions comply with GDPR ?

According to Rankiteo, Accelerated Enrollment Solutions is not listed as GDPR compliant.

Does Accelerated Enrollment Solutions have PCI DSS certification ?

According to Rankiteo, Accelerated Enrollment Solutions does not currently maintain PCI DSS compliance.

Does Accelerated Enrollment Solutions comply with HIPAA ?

According to Rankiteo, Accelerated Enrollment Solutions is not compliant with HIPAA regulations.

Does Accelerated Enrollment Solutions have ISO 27001 certification ?

According to Rankiteo,Accelerated Enrollment Solutions is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Accelerated Enrollment Solutions operate in ?

Accelerated Enrollment Solutions operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Accelerated Enrollment Solutions have ?

Accelerated Enrollment Solutions employs approximately 496 people worldwide.

Does Accelerated Enrollment Solutions own any subsidiaries ?

Accelerated Enrollment Solutions presently has no subsidiaries across any sectors.

How many LinkedIn followers does Accelerated Enrollment Solutions have ?

Accelerated Enrollment Solutions's official LinkedIn profile has approximately 32,927 followers.

What is the NAICS classification code for Accelerated Enrollment Solutions ?

Accelerated Enrollment Solutions is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Accelerated Enrollment Solutions have a Crunchbase profile ?

No, Accelerated Enrollment Solutions does not have a profile on Crunchbase.

Does Accelerated Enrollment Solutions have a LinkedIn profile ?

Yes, Accelerated Enrollment Solutions maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/accelerated-enrollment-solutions.

How many cybersecurity incidents has Accelerated Enrollment Solutions experienced ?

As of June 7, 2026, Rankiteo reports that Accelerated Enrollment Solutions has experienced 1 cybersecurity incidents.

How many peer or competitor companies does Accelerated Enrollment Solutions have ?

Accelerated Enrollment Solutions has an estimated 5,674 peer or competitor companies worldwide.

What types of cybersecurity incidents has Accelerated Enrollment Solutions faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

AES

Boost Score +25 with badge (5 left)

756

/1000

Fair

781

/1000

Fair

Accelerated Enrollment Solutions Vendor Cyber Rating & Cyber Score

trialmed.com

Add Your Compliance Badge

Accelerated Enrollment Solutions (AES) is now Trialmed. Follow us at our new home to understand how we're championing care in clinical research: https://www.linkedin.com/company/trialmed-solutions/ This account will not be active going forward.

AES A.I CyberSecurity Scoring

Scoring History

AES

Accelerated Enrollment Solutions CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Accelerated Enrollm...

Breach

7/2017

THE206072925

Loading…

A.I.

AES Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for AES

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Accelerated Enrollment Solutions in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Accelerated Enrollment Solutions in 2026.

Incident Types AES vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Accelerated Enrollment Solutions in 2026.

Incident History - AES (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Accelerated Enrollment Solutions Subsidiaries

AES

Pharmaceutical Manufacturing

Website: https://trialmed.com/

Company Size: 1,001-5,000 employees

PPDResearch Services

Thermo Fisher ScientificBiotechnology Research

PatheonPharmaceutical Manufacturing

Gallus BioPharmaceuticalsBiotechnology Research

Thermo ScientificBiotechnology Research

FEI CompanyNanotechnology Research

Accelerating MicroscopyBiotechnology

Unity Lab ServicesBiotechnology Research

Chromatography & Mass SpectrometryBiotechnology

Advancing MaterialsResearch Services

Fisher HealthcareHospitals and Health Care

Thermo Fisher Spectral CytometryBiotechnology Research

PPD™ Laboratory ServicesPharmaceutical Manufacturing

EvideraResearch Services

LiveTracker®Research Services

PPD™ Biotech SolutionsPharmaceutical Manufacturing

Loading…

Accelerated Enrollment Solutions Similar Companies

SUN PHARMA

sunpharma.com

Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/

Takeda

cb takeda.com

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

Novartis

cb novartis.com

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

Alembic Pharmaceuticals Limited

alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

Loading…

NEWS

Accelerated Enrollment Solutions CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

March 28, 2024 07:00 AM

Fastest Accelerated Online Bachelor’s of Cybersecurity

Want to earn an online bachelor's in cyber security, but need it quick? We rank the fastest online bachelor's degrees in cyber security in...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-26422

SUMMARY

clash-verge-service-ipc before 2.3.0 has a world-reachable IPC endpoint, leading to local privilege escalation.

Published

Date2026-06-06

Updated

Date2026-06-06

RISK INFORMATION (Score: 8.4)

cvss3

Base Score: 8.4

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

2.5

REFERENCES

CVE-2026-11441

SUMMARY

A vulnerability was identified in theonedev onedev up to 15.0.5. This vulnerability affects the function canAccessIssue of the file /issues/ of the component Pull Request Handler. Such manipulation of the argument issue leads to improper authorization. It is possible to launch the attack remotely. Upgrading to version 15.0.6 is able to resolve this issue. It is advisable to upgrade the affected component.

Published

Date2026-06-06

Updated

Date2026-06-06

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 5.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

CVE-2026-11440

SUMMARY

A vulnerability was determined in theonedev onedev up to 15.0.5. This affects an unknown part of the file /repositories/{projectId}/default-branch of the component REST API. This manipulation of the argument project.defaultBranch causes improper authorization. It is possible to initiate the attack remotely. Upgrading to version 15.0.6 is able to mitigate this issue. Upgrading the affected component is advised.

Published

Date2026-06-06

Updated

Date2026-06-06

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 5.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

CVE-2026-11439

SUMMARY

A vulnerability was found in theonedev onedev up to 15.0.5. Affected by this issue is some unknown functionality of the file /projects/ of the component Parent Project Handler. The manipulation of the argument project.parentId results in improper authorization. The attack may be performed from remote. Upgrading to version 15.0.6 can resolve this issue. It is recommended to upgrade the affected component.

Published

Date2026-06-06

Updated

Date2026-06-06

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 5.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

CVE-2026-11438

SUMMARY

A vulnerability has been found in theonedev onedev up to 15.0.5. Affected by this vulnerability is an unknown functionality of the file /projects. The manipulation of the argument project.forkedFromId leads to improper authorization. The attack is possible to be carried out remotely. Upgrading to version 15.0.6 addresses this issue. Upgrading the affected component is recommended.

Published

Date2026-06-06

Updated

Date2026-06-06

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 5.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…